A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer

Journal of Gynecologic Oncology

Volumn 24, Issue 2, 2013, Pages 154-159

  Isonishi, Seiji ^a   Suzuki, Masaaki ^b   Nagano, Hiroaki ^c   Takagi, Koichiro ^c   Shimauchi, Masahito ^d   Kawabata, Masakiyo ^d   Ochiai, Kazuhiko ^e  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b San ikukai General Hospital   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Fraternity Memorial Hospital Tokyo   (Japan)

^e Jikei University School of Medicine   (Japan)

Author keywords

Chemotherapy; Docetaxel; Maintenance; Ovarian cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; EDITORIAL; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; REPEATED DRUG DOSE; SENSORY NEUROPATHY; SURVIVAL RATE; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84885451568     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.2.154     Document Type: Editorial

References (11)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al., editors. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). Bethesda, MD: National Cancer Institute; 2011 [cited 2013 Feb 10]. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/.
4. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;98:1036-1045.
5. De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, et al. Topotecan compared with no therapy after response to surgery and carboplatin/ paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004;22:2635-2642.
6. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465.
7. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-2483.
8. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999;17:2069-2080.
9. Kaplan EL, Meier P. Nonparametric estimation from incom-plete observations. J Am Stat Assoc 1958;53:457-481.
10. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade- Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-2496.
11. Nakajima K, Isonishi S, Saito M, Tachibana T, Ishikawa H. Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines. Hum Cell 2010;23:156-163.